For Indian pharmaceutical companies, this scenario presents a distinct opportunity. Leveraging their established expertise and leadership in global COVID-19 vaccine distribution, along with robust supply chain efficiencies, Indian firms are strategically positioned to capitalize on this market shift. The departure of Chinese players from the market opens a significant gap, which Indian companies are well-equipped to fill .
BEL shares jump 4%, hit 52-week high after Nuvama raises target price post strong Q4 results
BEL shares: Nuvama highlighted that BEL’s Q4 margins improved to 30.6% from 26.7% quarter-on-quarter, exceeding market expectations of 24.7%. The management has reiterated its guidance
May 21, 2025